Get started
Astria Therapeutics, Inc.Astria Therapeutics, Inc.Astria Therapeutics, Inc.

Astria Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ATXS chart


Full chart

ATXS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪538.38 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.09 USD
Net income (FY)
‪−72.89 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪48.26 M‬
Beta (1Y)
2.39

Employees


Employees (FY)
59
Change (1Y)
+17 +40.48%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.24 M‬ USD

About Astria Therapeutics, Inc.


Sector
Health Technology
CEO
Jill C. Milne
Headquarters
Boston
Website
astriatx.com
Founded
2008
FIGI
BBG000QSGWX5
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ATXS news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ATXS is 9.54 USD — it has increased by 0.21% in the past 24 hours. Watch Astria Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Astria Therapeutics, Inc. stocks are traded under the ticker ATXS.
ATXS stock has fallen by −0.63% compared to the previous week, the month change is a 1.49% rise, over the last year Astria Therapeutics, Inc. has showed a 51.67% increase.
We've gathered analysts' opinions on Astria Therapeutics, Inc. future price: according to them, ATXS price has a max estimate of 35.00 USD and a min estimate of 16.00 USD. Watch ATXS chart and read a more detailed Astria Therapeutics, Inc. stock forecast: see what analysts think of Astria Therapeutics, Inc. and suggest that you do with its stocks.
ATXS reached its all-time high on Jul 6, 2015 with the price of 1,017.60 USD, and its all-time low was 2.36 USD and was reached on Jun 13, 2022. View more price dynamics on ATXS chart.
See other stocks reaching their highest and lowest prices.
ATXS stock is 3.38% volatile and has beta coefficient of 2.39. Track Astria Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Astria Therapeutics, Inc. there?
Today Astria Therapeutics, Inc. has the market capitalization of ‪538.38 M‬, it has decreased by −0.31% over the last week.
Yes, you can track Astria Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Astria Therapeutics, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
ATXS earnings for the last quarter are −0.42 USD per share, whereas the estimation was −0.42 USD resulting in a 0.40% surprise. The estimated earnings for the next quarter are −0.45 USD per share. See more details about Astria Therapeutics, Inc. earnings.
Astria Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ATXS net income for the last quarter is ‪−24.53 M‬ USD, while the quarter before that showed ‪−24.17 M‬ USD of net income which accounts for −1.50% change. Track more Astria Therapeutics, Inc. financial stats to get the full picture.
No, ATXS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 59.00 employees. See our rating of the largest employees — is Astria Therapeutics, Inc. on this list?
Like other stocks, ATXS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Astria Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Astria Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Astria Therapeutics, Inc. stock shows the strong sell signal. See more of Astria Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.